Respiratory syncytial virus (RSV) disease in hospitalised adults in Europe with COPD: Impact of GOLD score on RSV disease burden
Harrer T, Thalhammer F, Launay O, Cheret A, De La Rosa G, Sander I, Stolper R, Zakar J, Weber K (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 52
DOI: 10.1183/13993003.congress-2018.PA5309
Involved external institutions
Janssen-Cilag France
France (FR)
Janssen Pharmaceutica NV
Belgium (BE)
IQVIA Holdings, Inc.
United States (USA) (US)
Hôpital Cochin
France (FR)
Medizinische Universität Wien
Austria (AT)
France (FR)
Janssen Pharmaceutica NV
Belgium (BE)
IQVIA Holdings, Inc.
United States (USA) (US)
Hôpital Cochin
France (FR)
Medizinische Universität Wien
Austria (AT)
How to cite
APA:
Harrer, T., Thalhammer, F., Launay, O., Cheret, A., De La Rosa, G., Sander, I.,... Weber, K. (2018). Respiratory syncytial virus (RSV) disease in hospitalised adults in Europe with COPD: Impact of GOLD score on RSV disease burden.
MLA:
Harrer, Thomas, et al. "Respiratory syncytial virus (RSV) disease in hospitalised adults in Europe with COPD: Impact of GOLD score on RSV disease burden." 2018.
BibTeX: Download